| Completed | A Study to Investigate the Effect of Food on Camlipixant Concentrations in Healthy Participants Cough | Phase 1 | 2024-07-09 |
| Completed | A Study of Camlipixant in Male and Female Healthy Participants and Participants With Hepatic Impairment Aged 1 Cough | Phase 1 | 2024-02-02 |
| Completed | Evaluation of the Potential Drug-drug Interactions Between Gemfibrozil or Dabigatran Etexilate and Camlipixant Cough, Healthy | Phase 1 | 2023-07-26 |
| Completed | Evaluation of the Effect of Rifampin and Rabeprazole on the Pharmacokinetics of Camlipixant Cough, Healthy | Phase 1 | 2023-06-21 |
| Active Not Recruiting | A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough Cough, Refractory Chronic Cough | Phase 3 | 2022-12-05 |
| Active Not Recruiting | A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough Cough, Refractory Chronic Cough | Phase 3 | 2022-10-25 |
| Completed | Assessment of the Pharmacokinetics of BLU-5937 Extended Release Prototypes and a BLU-5937 Immediate Release Re Cough, Healthy | Phase 1 | 2022-10-07 |
| Completed | Evaluation of the Pharmacokinetics and Safety of BLU-5937 in Healthy Adult Japanese and Caucasian Subjects Healthy | Phase 1 | 2021-08-06 |
| Completed | A Multiple-Dose Study of BLU-5937 in Chronic Pruritus Associated With Atopic Dermatitis Chronic Pruritus, Atopic Dermatitis | Phase 2 | 2020-12-09 |
| Completed | Evaluation of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough Refractory Chronic Cough | Phase 2 | 2020-12-07 |
| Completed | Mass Balance Recovery, Absorption, Metabolism and Excretion of [14C]-BLU-5937 Healthy | Phase 1 | 2020-08-25 |
| Terminated | A Dose Escalation Study of BLU-5937 in Unexplained or Refractory Chronic Cough Chronic Refractory Cough | Phase 2 | 2019-07-10 |
| Completed | BLU-5937: First-in-Human, Single and Multiple Doses Escalation, Safety, Tolerability, Pharmacokinetics and Foo Cough | Phase 1 | 2018-07-09 |
| Completed | A Phase IIa Proof-of-concept Study of NC-503 in Patients With Type II Diabetes Diabetes Mellitus, Type 2, Metabolic Syndrome X | Phase 2 | 2008-04-01 |
| Unknown | Open-Label Extension of the Phase III Study With Tramiprosate (3APS) in Patients With Mild to Moderate Alzheim Alzheimer's Disease | Phase 3 | 2006-05-01 |
| Unknown | European Study of 3APS in Mild to Moderate Alzheimer's Disease Patients Alzheimer's Disease | Phase 3 | 2005-09-01 |
| Unknown | Evaluation of 3APS in Patients With Mild to Moderate Alzheimer's Disease Alzheimer Disease | Phase 3 | 2004-06-01 |
| Completed | Cerebril™ in Patients With Lobar Hemorrhage Related to Cerebral Amyloid Angiopathy Stroke, Neurologic Diseases, General | Phase 2 | 2003-02-01 |
| Completed | Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis Secondary (AA) Amyloidosis, Rheumatoid Arthritis, Nephrotic Syndrome | Phase 2 / Phase 3 | 2001-10-01 |